Improved diastolic function in type 2 diabetes after a six month liraglutide treatment

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: To investigate whether liraglutide improves diastolic function in type 2 diabetes. Methods: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6 months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6 months. Results: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2 ± 3.4 to 11.6 ± 4.7 cm/s (p <0.001) and from 6.9 ± 1.7 to 8.4 ± 2.6 cm/s (p <0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7 ± 0.3 to 0.9 ± 0.4 (p <0.001) and from 0.5 ± 0.1 to 0.6 ± 0.1 (p <0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7 ± 4.3 to 8.5 ± 2.5 (p <0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17 mmol/mol) vs -1.3% (-14 mmol/mol), p = 0.67. Conclusions: In patients with type 2 diabetes, 6 months liraglutide treatment was associated with a significant improvement in diastolic function.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume118
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Type 2 Diabetes Mellitus
Therapeutics
Control Groups
Hypoglycemic Agents
Observational Studies
Liraglutide
Prospective Studies
Glucose

Keywords

  • Diabetic cardiomyopathy
  • Diabetic heart disease
  • Diastolic dysfunction
  • GLP-1 receptor agonist
  • Liraglutide
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

@article{e6f01a45b0aa48988ffa1026767aea2f,
title = "Improved diastolic function in type 2 diabetes after a six month liraglutide treatment",
abstract = "Aims: To investigate whether liraglutide improves diastolic function in type 2 diabetes. Methods: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6 months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6 months. Results: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2 ± 3.4 to 11.6 ± 4.7 cm/s (p <0.001) and from 6.9 ± 1.7 to 8.4 ± 2.6 cm/s (p <0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7 ± 0.3 to 0.9 ± 0.4 (p <0.001) and from 0.5 ± 0.1 to 0.6 ± 0.1 (p <0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7 ± 4.3 to 8.5 ± 2.5 (p <0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5{\%} (-17 mmol/mol) vs -1.3{\%} (-14 mmol/mol), p = 0.67. Conclusions: In patients with type 2 diabetes, 6 months liraglutide treatment was associated with a significant improvement in diastolic function.",
keywords = "Diabetic cardiomyopathy, Diabetic heart disease, Diastolic dysfunction, GLP-1 receptor agonist, Liraglutide, Type 2 diabetes",
author = "Fabio Saponaro and Andrea Sonaglioni and Antonio Rossi and Laura Montefusco and Michele Lombardo and Guido Adda and Maura Arosio",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.diabres.2016.04.046",
language = "English",
volume = "118",
pages = "21--28",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Improved diastolic function in type 2 diabetes after a six month liraglutide treatment

AU - Saponaro, Fabio

AU - Sonaglioni, Andrea

AU - Rossi, Antonio

AU - Montefusco, Laura

AU - Lombardo, Michele

AU - Adda, Guido

AU - Arosio, Maura

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Aims: To investigate whether liraglutide improves diastolic function in type 2 diabetes. Methods: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6 months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6 months. Results: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2 ± 3.4 to 11.6 ± 4.7 cm/s (p <0.001) and from 6.9 ± 1.7 to 8.4 ± 2.6 cm/s (p <0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7 ± 0.3 to 0.9 ± 0.4 (p <0.001) and from 0.5 ± 0.1 to 0.6 ± 0.1 (p <0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7 ± 4.3 to 8.5 ± 2.5 (p <0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17 mmol/mol) vs -1.3% (-14 mmol/mol), p = 0.67. Conclusions: In patients with type 2 diabetes, 6 months liraglutide treatment was associated with a significant improvement in diastolic function.

AB - Aims: To investigate whether liraglutide improves diastolic function in type 2 diabetes. Methods: Thirty-seven patients with type 2 diabetes who began liraglutide therapy between June 2013 and May 2014 were enrolled in this observational, prospective study. 26 patients received liraglutide therapy for at least 6 months. The remaining 11 patients withdrew from liraglutide therapy during the first month, were started on other hypoglycaemic therapies and formed the control group. Anthropometric, metabolic and echocardiographic parameters including pulsed wave tissue Doppler imaging were evaluated at baseline and at 6 months. Results: In the liraglutide group the early diastolic mitral annulus velocity on the lateral (e-lat) and medial (e-med) sides of the mitral annulus increased from 9.2 ± 3.4 to 11.6 ± 4.7 cm/s (p <0.001) and from 6.9 ± 1.7 to 8.4 ± 2.6 cm/s (p <0.003), respectively. The ratio of early-to-late velocities on the lateral and medial sides of the mitral annulus increased from 0.7 ± 0.3 to 0.9 ± 0.4 (p <0.001) and from 0.5 ± 0.1 to 0.6 ± 0.1 (p <0.02), respectively. The ratio of early diastolic mitral inflow velocity to early diastolic myocardial relaxation velocity decreased from 10.7 ± 4.3 to 8.5 ± 2.5 (p <0.005). No improvements in diastolic function was detected in the control group. Glucose control improved similarly in both groups: HA1bc -1.5% (-17 mmol/mol) vs -1.3% (-14 mmol/mol), p = 0.67. Conclusions: In patients with type 2 diabetes, 6 months liraglutide treatment was associated with a significant improvement in diastolic function.

KW - Diabetic cardiomyopathy

KW - Diabetic heart disease

KW - Diastolic dysfunction

KW - GLP-1 receptor agonist

KW - Liraglutide

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84969257362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969257362&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2016.04.046

DO - 10.1016/j.diabres.2016.04.046

M3 - Article

VL - 118

SP - 21

EP - 28

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -